MA32480B1 - Compositions pédiatriques pour le traitement de la sclérose en plaques - Google Patents

Compositions pédiatriques pour le traitement de la sclérose en plaques

Info

Publication number
MA32480B1
MA32480B1 MA33524A MA33524A MA32480B1 MA 32480 B1 MA32480 B1 MA 32480B1 MA 33524 A MA33524 A MA 33524A MA 33524 A MA33524 A MA 33524A MA 32480 B1 MA32480 B1 MA 32480B1
Authority
MA
Morocco
Prior art keywords
treatment
children
compositions
multiple sclerosis
sclerosis
Prior art date
Application number
MA33524A
Other languages
Arabic (ar)
English (en)
Inventor
Marie-Claude Bastien
John Kovarik
Robert Schmouder
Olivier David
Goeril Karlsson
Thomas Bouillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32480(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32480B1 publication Critical patent/MA32480B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comportent un composé de 2-amino-2-[2-(4-c2-20-alkyl-phényl)éthyl]propane-1,3-diol ou un sel de qualité pharmaceutique de celui-ci, et l'utilisation de celui-ci pour traiter, prévenir ou retarder la progression d'une sclérose en plaques chez un patient pédiatrique ou un patient souffrant d'un état précis.
MA33524A 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques MA32480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20
PCT/US2009/047885 WO2009155475A1 (fr) 2008-06-20 2009-06-19 Compositions pédiatriques pour le traitement de la sclérose en plaques

Publications (1)

Publication Number Publication Date
MA32480B1 true MA32480B1 (fr) 2011-07-03

Family

ID=40974366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33524A MA32480B1 (fr) 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques

Country Status (16)

Country Link
US (11) US20110152380A1 (fr)
EP (3) EP3545953A1 (fr)
JP (7) JP2011525189A (fr)
KR (4) KR20160131126A (fr)
CN (2) CN102076335A (fr)
BR (1) BRPI0914139A2 (fr)
CA (1) CA2728514C (fr)
CL (1) CL2010001463A1 (fr)
IL (2) IL209725A (fr)
MA (1) MA32480B1 (fr)
MX (1) MX2010014223A (fr)
NZ (1) NZ589618A (fr)
RU (1) RU2562571C2 (fr)
SG (1) SG10201406263SA (fr)
WO (1) WO2009155475A1 (fr)
ZA (1) ZA201008478B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152380A1 (en) 2008-06-20 2011-06-23 Kovarik John M Paediatric Compositions For Treating Multiple Sclerosis
EP2356090B1 (fr) * 2008-11-11 2017-07-05 Novartis AG Formes crystallines de fingolimod hcl
LT3453387T (lt) * 2008-12-22 2020-08-25 Novartis Ag S1p receptoriaus antagonisto dozavimo režimas
WO2011041146A2 (fr) 2009-09-29 2011-04-07 Novartis Ag Schéma posologique d'un modulateur des récepteurs de s1p
MX2016001422A (es) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Composicion farmaceutica de fingolimod.

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
AU2560000A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin
JP2002537293A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌおよび／またはカテプシンｓの阻害剤としてのアセタミドアセトニトリル誘導体
EP1159273A1 (fr) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (fr) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Traitement combiné de l'esclerose multiple avec l'interferon et l'hormone de croissance
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
WO2001014387A1 (fr) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. Analogues d'epirapamycine-28
WO2001019796A1 (fr) 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Composes et compositions pharmaceutiques utilises comme inhibiteurs de la cathepsine s
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
AU2001281255B2 (en) 2000-08-14 2006-07-20 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6635633B2 (en) 2000-08-14 2003-10-21 Ortho-Pharmaceutical, Inc. Substituted pyrazoles
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
EP1326848A1 (fr) 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Derives de dihydropyrimidine utilises comme inhibiteurs de cysteine protease
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
MXPA04002282A (es) 2001-09-14 2005-03-07 Axis Pharmaceutical Inc Nuevos compuestos y preparaciones como inhibidores de la catepsina.
WO2003024923A1 (fr) 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Composes sulfonamide en tant qu'inhibiteurs de protease
US6936606B2 (en) 2001-10-02 2005-08-30 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6841571B2 (en) 2001-10-29 2005-01-11 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003041649A2 (fr) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease
RU2004117877A (ru) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) Олигопептиды и композиции, содержащие их, в качестве ингибиторов катепсина s
EP1389480A1 (fr) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
US20060046979A1 (en) * 2002-09-24 2006-03-02 Foster Carolyn A Organic compounds
PL2316431T3 (pl) 2003-04-08 2016-09-30 Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy
US20050009052A1 (en) * 2003-04-22 2005-01-13 Irm Llc, A Delaware Limited Liability Company Differential tag length analysis of cell proliferation
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2007302296A1 (en) 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
US20110152380A1 (en) 2008-06-20 2011-06-23 Kovarik John M Paediatric Compositions For Treating Multiple Sclerosis

Also Published As

Publication number Publication date
JP2011525189A (ja) 2011-09-15
US20180177747A1 (en) 2018-06-28
IL248919A0 (en) 2017-01-31
US20160206574A1 (en) 2016-07-21
CA2728514C (fr) 2020-08-11
SG10201406263SA (en) 2015-02-27
RU2562571C2 (ru) 2015-09-10
IL248919B (en) 2018-12-31
US20200197334A1 (en) 2020-06-25
KR20160131126A (ko) 2016-11-15
CN104800196A (zh) 2015-07-29
WO2009155475A1 (fr) 2009-12-23
CA2728514A1 (fr) 2009-12-23
US20210023027A1 (en) 2021-01-28
IL209725A (en) 2016-11-30
JP2018184424A (ja) 2018-11-22
MX2010014223A (es) 2011-01-21
KR20170081755A (ko) 2017-07-12
CN102076335A (zh) 2011-05-25
JP2017122106A (ja) 2017-07-13
EP2303250A1 (fr) 2011-04-06
IL209725A0 (en) 2011-02-28
US20190117593A1 (en) 2019-04-25
RU2011101771A (ru) 2012-07-27
US20170333368A1 (en) 2017-11-23
US20160022611A1 (en) 2016-01-28
JP2021152016A (ja) 2021-09-30
US20110152380A1 (en) 2011-06-23
EP3545953A1 (fr) 2019-10-02
US20190358178A1 (en) 2019-11-28
US20170128389A1 (en) 2017-05-11
JP2020063269A (ja) 2020-04-23
KR20110020928A (ko) 2011-03-03
US20130230489A1 (en) 2013-09-05
KR20180017232A (ko) 2018-02-20
BRPI0914139A2 (pt) 2015-10-20
NZ589618A (en) 2012-09-28
JP2015107984A (ja) 2015-06-11
EP3011958A1 (fr) 2016-04-27
AU2009259950A1 (en) 2009-12-23
JP2023153786A (ja) 2023-10-18
CL2010001463A1 (es) 2011-05-06
ZA201008478B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA200900105A1 (ru) Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
WO2010036395A3 (fr) Traitement de l’exposition aux organophosphates au moyen de composés de tétrahydroindolone arylpipérazine
MY148495A (en) Oral compositions for treating tooth sensitivity and methods of use and manufacture thereof
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2013098416A3 (fr) Composes anti-douleur
MA32480B1 (fr) Compositions pédiatriques pour le traitement de la sclérose en plaques
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
EA201170267A1 (ru) Способ лечения гиперчувствительности зубов
WO2012100043A3 (fr) Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
WO2013062442A3 (fr) Composition pour traiter la sclérose en plaques (et variantes)
UA113975C2 (xx) Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти)